Session Information
Free- CMES01 What's New in Osteoporosis Diagnosis and Treatment
Click here to go to the previous page
What's New in Osteoporosis Diagnosis and Treatment
Track
:
Session
Program Code:
CMES01
Date:
Thursday, June 11, 2009
Time:
6:30 PM to 9:30 PM
EST
SPEAKER
(S):
Michael R. McClung, MD, Strengths and Limitations of the FRAX Risk Prediction in Osteoporosis Diagnosis & Treatment, Oregon Osteoporosis Center
E. Michael Lewiecki, MD, PhD, New Mexico Clinical Research & Osteoporosis CenterDisclosure: research grant support from Amgen, Eli Lilly, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Procter & Gamble, Roche, and sanofi-aventis; financial support for serving as a scientific advisory board member for Amgen, Eli Lilly, Novartis Pharmaceuticals Corporation, Roche/GSK, Upsher-Smith, and Wyeth; financial support for serving on speakers bureaus for Eli Lilly, Novartis and Roche/GSK; owns stock in General Electric, Proctor & Gamble, and Teva.
John P. Bilezikian, MD, Columbia Univ Coll of Phys & Surg
Disclosure: has received consulting fees from Eli Lilly, Novartis, Alliance for Better Bone Health, NPS Pharmaceuticals, Merck and Amgen and speaker fees from Eli Lilly, Novartis, and the Alliance for Better Bone Health.
Disclosure: has received consulting fees from Eli Lilly, Novartis, Alliance for Better Bone Health, NPS Pharmaceuticals, Merck and Amgen and speaker fees from Eli Lilly, Novartis, and the Alliance for Better Bone Health.
Audio Synchronized to PowerPoint
